Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mindbio Therapeutics Corp. ( (TSE:MBIO) ) has shared an update.
MindBio Therapeutics Corp. announced that CEO Justin Hanka will present at the 9th Annual Neuroscience Innovation Forum in San Francisco, coinciding with a broader Silicon Valley roadshow during JP Morgan Healthcare Conference week. The company will use the event to showcase its AI-powered, voice-activated intoxication detection technology, which is built on more than 50 million data points and can predict alcohol intoxication and estimate blood alcohol concentration levels, underpinning the forthcoming Booze AI app. MindBio is also developing an enterprise platform for health prediction using the human voice, targeting workplace environments, call centres, mental health settings and law enforcement, signalling a push to broaden its product portfolio and commercial footprint across multiple safety- and health-critical markets.
More about Mindbio Therapeutics Corp.
MindBio Therapeutics Corp. is a Vancouver-based, clinical-stage biotechnology company focused on developing novel treatments for mental health disorders and health prediction technologies using AI and machine learning. The company specializes in speech analytics as a tool for detecting and predicting drug and alcohol intoxication, leveraging large-scale voice data to build predictive models for healthcare and safety applications.
Average Trading Volume: 3,135
Technical Sentiment Signal: Hold
Current Market Cap: C$2.56M
For an in-depth examination of MBIO stock, go to TipRanks’ Overview page.